First Patient Dosed in MYCHELANGELO™ I Trial of OTX-2002 in HCC and Other Solid Tumors with MYC Oncogene November 4, 2022
First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients October 26, 2022
Ph I part of the clinical trial of Bria-IMT™, in combination with retifanlimab, in advanced breast cancer completed October 26, 2022
New Patient Enrollment in Ph 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas paused after patient death October 26, 2022
Development of CYAD-101, Allogeneic TIM-based, NKG2D CAR T Candidate for Metastatic Colorectal Cancer (mCRC), to be discontinued October 19, 2022
Enrollment Completed in Global Multi-Center Ph 3 Clinical Trial of Trilaciclib in Patients with mTNBC October 19, 2022
First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Ph 1/2/3 Clinical Study for Natrunix™ Therapy for Colorectal Cancer October 19, 2022
First Patient Enrolled in Part C of Ph 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer October 19, 2022
First US Patient Dosed in TILT-123 Immunotherapy Ph 1 Clinical Trial in Ovarian Cancer October 19, 2022
Ph 2 Trial of DNA-Damaging Agent PLX038 initiated in patients with Platinum-Resistant Ovarian Cancer October 12, 2022
First Allogeneic CAR T Ph 2 ALPHA2 Trial of ALLO-501A in R/R LBCL Patients initiated October 12, 2022
Ph 1/2 Trial of ABC008 initiated in Patients with T Cell Large Granular Lymphocytic Leukemia October 12, 2022
First Patient Treated in Ph 1/2 Clinical Trial of MB-106 in B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia October 12, 2022
Part 3 of the CORIST Ph 2 trial of SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC) initiated October 12, 2022
Randomized Ph 2 trial of onvansertib + SoC FOLFIRI/bevacizumab announced in 2L RAS-mutated mCRC September 28, 2022
Pivotal Ph 3 Trial of Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer initiated September 28, 2022
Enrollment of the Ph 1/2 OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer completed September 28, 2022
First Patient Dosed In Ph 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3 September 7, 2022
Enrollment initiated in Ph 2 Trial of Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma September 7, 2022
Ph 2 SCOPE trial of SCIB1 vaccine in metastatic melanoma patients expanded; additional cohort to test SCIB1 vaccine in combination with checkpoint doublet therapy June 16, 2022
FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab June 14, 2022
